enGene reports Cohort 1 LEGEND data and FDA alignment; CG Oncology awaits PIVOT-006 readoutNov 16Clinical readoutCG Oncology, Inc.enGene, Inc.Updated
enGene reports Q3 2026 results, keeps 4Q BLA-related timelines for detalimogeneSep 8Quarterly updateenGene, Inc.
FDA approves efficacy supplement for Eli Lilly's Retevmo (selpercatinib)Jul 14Regulatory decisionEli LillyenGene, Inc.